The new Research Activity League Table from the NIHR Clinical Research Network shows all NHS trusts or hospital groups in England are delivering clinical research and over 60% increased their research activity last year.
The new Research Activity League Table from the National Institute for Health Research (NIHR) Clinical Research Network (CRN) shows all National Health Service (NHS) trusts or hospital groups in England are delivering clinical research and over 60% increased their research activity last year.
Commercial research activity is an added feature for the 2015/16 league table, which found that 36% of studies were new commercial contract studies last year.
“This year’s league table results highlight for the first time the growing importance of commercial research for the NHS in England,” said Dr. Jonathan Sheffield, Chief Executive Officer of the NIHR CRN. “Commercial involvement in clinical research speeds up the development and availability of new treatments, therapies and diagnostics for NHS patients. The U.K. is a destination of choice with 35,000 participants recruited to studies sponsored by the life sciences industry in England last year.”
Barts Health NHS Trust in London came top of the league table for the amount of commercial studies delivered (114 studies), and also had the biggest increase in studies from last year (279 to 335), along with Imperial College Healthcare NHS Trust (365 to 421).
The following NHS trust types were ranked top in terms of the largest quantity of research for 2015/16:
The top five trusts achieving the biggest step-change in research activity (study increase) were as follows:
The National Institute for Health Research (NIHR) is funded by the Department of Health, and is the research arm of the NHS. It was established in April 2006. To view the full league table, go to www.nihr.ac.uk/nihrleaguetable.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.